Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity-Reference-Cited by-同舟云学术

Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity

Published:2024-07-06 Issue:8 Volume:44 Page:884-888
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Choi Sung Hee¹²^ORCID,Myers Jay Thomas¹,Tomchuck Suzanne Louise¹,Bonner Melissa³,Eid Saada¹,Kingsley Daniel Tyler³,VanHeyst Kristen Ashley¹²,Kim Seong‐Jin⁴,Kim Byung‐Gyu¹²,Huang Alex Yee‐Chen¹²³⁵^ORCID

Affiliation:

1. Department of Pediatrics Case Western Reserve University School of Medicine Cleveland Ohio USA

2. Case Comprehensive Cancer Center Case Western Reserve University School of Medicine Cleveland Ohio USA

3. Department of Pathology Case Western Reserve University School of Medicine Cleveland Ohio USA

4. MedPacto Inc. Seoul Republic of Korea

5. Center for Pediatric Immunotherapy, Angie Fowler AYA Cancer Institute, UH Rainbow Babies and Children's Hospital Cleveland Ohio USA

Funder

National Cancer Institute

St. Baldrick's Foundation

Andrew McDonough B+ Foundation

Curing Kids Cancer

MIB Agents

Sarcoma Foundation of America

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12589

Reference10 articles.

1. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival

2. Transforming Growth Factor-Beta Polymorphisms and Serum Level in the Development of Osteosarcoma

3. Novel therapies emerging in oncology to target the TGF-β pathway

4. EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis

5. Induced resistance to ifosfamide in osteosarcoma cells suggests a more aggressive tumor profile;Oliveira Rodrigues MT;Biochem Biophys Rep,2022